Israeli company KAHR Medical, which develops treatments for cancer and inflammatory disease, specifically lymphoma, has announced that it has raised $2.35 million from its shareholders at a company value of $13.2 million.
The company intends to use the proceeds in order to begin human trials in early 2014.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments